Wall Street brokerages predict that Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) will announce earnings per share (EPS) of ($0.35) for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Adaptimmune Therapeutics’ earnings, with estimates ranging from ($0.40) to ($0.29). Adaptimmune Therapeutics reported earnings per share of ($0.48) during the same quarter last year, which would suggest a positive year over year growth rate of 27.1%. The firm is scheduled to report its next quarterly earnings results on Thursday, August 1st.
According to Zacks, analysts expect that Adaptimmune Therapeutics will report full year earnings of ($1.17) per share for the current financial year, with EPS estimates ranging from ($1.34) to ($0.94). For the next financial year, analysts forecast that the business will report earnings of ($1.16) per share, with EPS estimates ranging from ($1.45) to ($0.83). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Adaptimmune Therapeutics.
Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its quarterly earnings results on Monday, May 6th. The biotechnology company reported ($0.24) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.04. Adaptimmune Therapeutics had a negative net margin of 161.09% and a negative return on equity of 45.03%.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. D. E. Shaw & Co. Inc. purchased a new position in shares of Adaptimmune Therapeutics in the fourth quarter valued at $1,231,000. Baillie Gifford & Co. raised its holdings in shares of Adaptimmune Therapeutics by 3.8% in the first quarter. Baillie Gifford & Co. now owns 3,839,190 shares of the biotechnology company’s stock valued at $16,508,000 after acquiring an additional 139,669 shares in the last quarter. Deutsche Bank AG raised its holdings in shares of Adaptimmune Therapeutics by 1,681,328.6% in the fourth quarter. Deutsche Bank AG now owns 117,700 shares of the biotechnology company’s stock valued at $676,000 after acquiring an additional 117,693 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of Adaptimmune Therapeutics in the fourth quarter valued at about $622,000. Finally, BlackRock Inc. grew its stake in Adaptimmune Therapeutics by 10.4% in the fourth quarter. BlackRock Inc. now owns 856,415 shares of the biotechnology company’s stock valued at $4,924,000 after purchasing an additional 81,010 shares during the last quarter. 66.30% of the stock is owned by institutional investors and hedge funds.
NASDAQ:ADAP opened at $3.63 on Friday. The firm’s fifty day moving average price is $3.62. Adaptimmune Therapeutics has a 52 week low of $3.20 and a 52 week high of $14.54. The company has a quick ratio of 8.55, a current ratio of 8.55 and a debt-to-equity ratio of 0.12. The company has a market cap of $382.12 million, a price-to-earnings ratio of -3.78 and a beta of 1.63.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.
Featured Story: Understanding Specialty Certificates of Deposit
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.